Oncology firm TransCode Therapeutics prices 6.25M-share IPO at $4

TransCode Therapeutics (RNAZ) has priced its initial public offering of 6.25 million common shares at $4.00 per share, raising $25 million in gross proceeds. An additional 937.5K shares have been over-allotted by the underwriters./nRead More